NASDAQ:ALMS Alumis Q2 2025 Earnings Results & Report $6.62 +0.22 (+3.44%) Closing price 04:00 PM EasternExtended Trading$6.42 -0.20 (-3.02%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alumis missed analyst earnings expectations but beat on revenue in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$1.17 versus the -$1.11 consensus estimate, while revenue of $2.67 million topped the $1.80 million estimate by $866.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 13, 2025TimeBefore Market OpensConference Call4:00 PM ET Alumis EPS ResultsActual EPS-$1.17Consensus EPS -$1.11Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate0 of last 7 quartersAlumis Revenue ResultsActual Revenue$2.67 millionExpected Revenue$1.80 millionBeat/MissBeat by +$866.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAlumis' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alumis Q2 2025 Earnings FAQ Did Alumis beat earnings estimates for Q2 2025? Alumis (NASDAQ:ALMS) reported earnings of -$1.17 per share for Q2 2025, missing the consensus estimate of -$1.11. The report was announced on Wednesday, August 13, 2025. What was Alumis' revenue for Q2 2025? Alumis reported revenue of $2.67 million for Q2 2025, against a consensus estimate of $1.80 million. When is Alumis' next earnings date? Alumis' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alumis on the company's earnings history page. Alumis Earnings HeadlinesAlumis (ALMS) Expected to Release Quarterly Earnings on ThursdayNovember 11 at 3:44 AM | americanbankingnews.comAlumis Inc. (NASDAQ:ALMS) Stock Has Consensus Price Target of $33.27November 6, 2026 | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 11 at 1:00 AM | Traders Agency (Ad)Alumis’ Phase 3 Psoriasis Trial Reaches Completion, Raising the Stakes for ALMS InvestorsOctober 28, 2026 | tipranks.comAlumis Caps Key Psoriasis Trial, Raising Stakes for ALMS InvestorsOctober 28, 2026 | tipranks.comAlumis Reports Positive Phase 3 Data With EnvudeucitinibOctober 9, 2026 | rttnews.comSee More Alumis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alumis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alumis and other key companies, straight to your email. Email Address About AlumisAlumis (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use. Alumis was formed in 2024 through the combination of Esker Therapeutics and Kintara Therapeutics and is based in South San Francisco, California. Its work includes conducting clinical trials and developing potential treatments for patients with inflammatory and autoimmune conditions.View Alumis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
